Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06137196
Recruiting Observational

Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia

NCT06137196 · tracked via the Priya Life Science China tracker
Sponsor
Guangzhou 8th People's Hospital
Phase
Observational
Started
2023-11-01
Last updated
2023-11-18

Condition(s) studied

AIDSPneumonia

Study summary

Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Confirmed HIV infection; 2. Progression to the AIDS stage: CD4+ count \<200 cells/µL and/or occurrence of opportunistic infections associated with AIDS; 3. Age between 18 to 65 years; 4. Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). Exclusion Criteria: 1. Concurrent central nervous system lesions, severe liver disease, or cirrhosis; 2. Concurrent AIDS-related or non-related tumors; 3. Women who are pregnant or breastfeeding; 4. Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.; 5. Alcohol abuse or drug use; 6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial

Primary outcome measure(s)

  • Obstructive Ventilatory Dysfunction — 12 weeks
    FEV1(Forced Expiratory Volume in One Second )to FVC (Forced Vital Capacity ) Ratio

Trial sites (1)

FacilityCityRegionStatus
Guangzhou Eighth People's Hospital, Guangzhou Medical University Guangzhou Guangdong Recruiting

More Guangzhou 8th People's Hospital trials in China

Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads Recruiting
Simplified Treatment of Anti-retrovirus in China (C-STAR) Recruiting
Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock Recruiting
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function Recruiting
Observational Study on Patients With HIV/AIDS(OSPWH) Recruiting

Other trials for the same condition

A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia Recruiting
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage Recruiting
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Starting soon
Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study Recruiting
Modified Inhaled Nitric Oxide in Ventilated Patients With Acute Respiratory Failure Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06137196 on ClinicalTrials.gov ↗ ← All trials in China